OBJECTIVE: Genetic linkage studies in schizophrenia (SZ) have primarily focused on the phenotype of disease susceptibility. A limited number of studies, however, have reported suggestive linkage to specific SZ symptom domains including regions on chromosomes 6, 8, and 20. We examined these chromosomal regions for association to positive, negative, and disorganized symptom clusters, using a dense set of single-nucleotide polymorphisms (SNPs). METHODS: We ascertained 178 Caucasian patients with SZ for lifetime severity of clinical symptomatology using a structured diagnostic interview. The cohort was genotyped with the Affymetrix 500K microarray, from which we selected, a priori, 4833 intragenic SNPs located within chromosomal regions previously linked to specific SZ symptom clusters. Parametric tests, corrected for multiple testing, were used to compare the effects of allelic variation within these SNPs to the lifetime severity of the specific symptom domain that had been implicated by prior linkage studies. RESULTS: We were able to extend previous reports of linkage between chromosome 6q and both positive and disorganized symptoms. Lifetime severity of positive symptoms was significantly (P = 2.50 x 10(-5)) associated with a SNP within the origin recognition complex subunit 3-like (ORC3L) gene, a gene implicated in synaptic plasticity. Level of disorganized symptoms was significantly (P < 6.00 x 10(-5)) associated 2 SNPs within the brain-specific angiogenesis inhibitor 3 (BAI3) gene, which is highly expressed in brain during development. CONCLUSIONS: These data point toward specific candidate genes located within previously implicated linkage peaks for clinical symptomatology. Identification of functional variants within these regions and a characterization of the effect of these risk genotypes on the treatment of specific clinical symptoms are needed.
OBJECTIVE: Genetic linkage studies in schizophrenia (SZ) have primarily focused on the phenotype of disease susceptibility. A limited number of studies, however, have reported suggestive linkage to specific SZ symptom domains including regions on chromosomes 6, 8, and 20. We examined these chromosomal regions for association to positive, negative, and disorganized symptom clusters, using a dense set of single-nucleotide polymorphisms (SNPs). METHODS: We ascertained 178 Caucasian patients with SZ for lifetime severity of clinical symptomatology using a structured diagnostic interview. The cohort was genotyped with the Affymetrix 500K microarray, from which we selected, a priori, 4833 intragenic SNPs located within chromosomal regions previously linked to specific SZ symptom clusters. Parametric tests, corrected for multiple testing, were used to compare the effects of allelic variation within these SNPs to the lifetime severity of the specific symptom domain that had been implicated by prior linkage studies. RESULTS: We were able to extend previous reports of linkage between chromosome 6q and both positive and disorganized symptoms. Lifetime severity of positive symptoms was significantly (P = 2.50 x 10(-5)) associated with a SNP within the origin recognition complex subunit 3-like (ORC3L) gene, a gene implicated in synaptic plasticity. Level of disorganized symptoms was significantly (P < 6.00 x 10(-5)) associated 2 SNPs within the brain-specific angiogenesis inhibitor 3 (BAI3) gene, which is highly expressed in brain during development. CONCLUSIONS: These data point toward specific candidate genes located within previously implicated linkage peaks for clinical symptomatology. Identification of functional variants within these regions and a characterization of the effect of these risk genotypes on the treatment of specific clinical symptoms are needed.
Authors: A G Cardno; T Bowen; C A Guy; L A Jones; G McCarthy; N M Williams; K C Murphy; G Spurlock; M Gray; R D Sanders; N Craddock; P McGuffin; M J Owen; M C O'Donovan Journal: Biol Psychiatry Date: 1999-06-15 Impact factor: 13.382
Authors: Todd Lencz; Christophe Lambert; Pamela DeRosse; Katherine E Burdick; T Vance Morgan; John M Kane; Raju Kucherlapati; Anil K Malhotra Journal: Proc Natl Acad Sci U S A Date: 2007-12-05 Impact factor: 11.205
Authors: James B Potash; Peter P Zandi; Virginia L Willour; Tsuo-Hung Lan; Yuqing Huo; Dimitrios Avramopoulos; Yin Y Shugart; Dean F MacKinnon; Sylvia G Simpson; Francis J McMahon; J Raymond DePaulo; Melvin G McInnis Journal: Am J Psychiatry Date: 2003-04 Impact factor: 18.112
Authors: K S Kendler; J M Myers; F A O'Neill; R Martin; B Murphy; C J MacLean; D Walsh; R E Straub Journal: Am J Psychiatry Date: 2000-03 Impact factor: 18.112
Authors: Ayman H Fanous; M C Neale; R E Straub; B T Webb; A F O'Neill; D Walsh; K S Kendler Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2004-02-15 Impact factor: 3.568
Authors: Pamela DeRosse; Birgit Funke; Katherine E Burdick; Todd Lencz; Jenny M Ekholm; John M Kane; Raju Kucherlapati; Anil K Malhotra Journal: Am J Psychiatry Date: 2006-03 Impact factor: 18.112
Authors: David C Martinelli; Kylie S Chew; Astrid Rohlmann; Matthew Y Lum; Susanne Ressl; Samer Hattar; Axel T Brunger; Markus Missler; Thomas C Südhof Journal: Neuron Date: 2016-07-28 Impact factor: 17.173
Authors: Tim R Mercer; Irfan A Qureshi; Solen Gokhan; Marcel E Dinger; Guangyu Li; John S Mattick; Mark F Mehler Journal: BMC Neurosci Date: 2010-02-05 Impact factor: 3.288
Authors: Joseph G Duman; Christopher P Tzeng; Yen-Kuei Tu; Tina Munjal; Brandon Schwechter; Tammy Szu-Yu Ho; Kimberley F Tolias Journal: J Neurosci Date: 2013-04-17 Impact factor: 6.167